Publication | Open Access
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
170
Citations
25
References
2020
Year
Ivosidenib plus azacitidine was well tolerated, with an expected safety profile consistent with monotherapy with each agent. Responses were deep and durable, with most complete responders achieving m<i>IDH1</i> mutation clearance.
| Year | Citations | |
|---|---|---|
Page 1
Page 1